News

  The global livestock and aquaculture sectors have maintained steady growth in recent years, which has directly boosted the market demand for veterinary pharmaceuticals, biological vaccines and related animal health products across the world. As large-scale, intensive and standardized farming modes gradually replace traditional breeding methods, breeders and agricultural operators around the world have raised higher standards for the safety, efficacy and stability of animal medicines. Products covering poultry vaccines, livestock vaccines, antibacterial injections, soluble powders, antiparasitic agents and environmental disinfectants are all witnessing sustained growth in export volume.     Regulatory policies vary from region to region, yet compliance has universally become the top priority for the whole industry. Major overseas markets including the Middle East, South Asia, Southeast Asia and European countries have formulated complete sets of access rules for imported veterinary products. Strict requirements are imposed on production environment, quality management system, product test reports and technical dossiers. Enterprises engaged in foreign trade of veterinary products have to keep pace with updated regulations, optimize production procedures in line with GMP guidelines, and strengthen full-process quality control from raw material procurement to finished product delivery.     Industry insiders believe that the upward trend of veterinary product foreign trade will continue in the long run. Markets in emerging economies still have huge potential to be tapped, while mature markets focus more on high-end products and innovative biological vaccines. Only those who attach importance to product quality, keep learning international regulatory rules and build stable supply chains can seize more development opportunities in the fiercely competitive global market.

  International professional exhibitions focused on animal health and veterinary products have long been recognized as one of the most efficient platforms for trade connection, technical exchange and industry cooperation. Every year, a series of influential exhibitions are held in different countries and regions, gathering manufacturers, distributors, purchasing groups, technical experts and regulatory consultants from all over the animal health industry chain. These events create face-to-face communication opportunities and greatly accelerate the development of cross-border trade of veterinary drugs and vaccines.     During the exhibitions, exhibitors fully display their mainstream products, new research achievements and customized solutions. Attendees can learn about the latest product formulas, application effects and production technologies on site. Meanwhile, participants also exchange in-depth views on market changes, consumer demands and industry development directions. Many long-term cooperative partnerships are established through in-depth negotiations at exhibitions, covering product distribution, exclusive agency, joint research and market co-development.     Apart from business cooperation, exhibitions also act as an important window to understand overseas regulatory policies. Professionals from different regions share experiences in product registration, document preparation and market entry. For practitioners engaged in foreign trade, participating in international exhibitions is not only a way to expand customer resources, but also an important channel to update industry information and adjust market strategies. As cross-border trade becomes increasingly frequent, the value of such industry events will become more prominent, continuously driving the interconnected development of the global veterinary industry.    

    In the current global market competition, product innovation has become a core driving force to expand the overseas trade of veterinary drugs and vaccines. Against the backdrop of frequent animal epidemic diseases and rising requirements for breeding safety, the market has shown strong demand for high-efficiency, low-residue, environment-friendly veterinary products and multi-combination vaccines. Traditional single-function products can no longer fully meet the diversified needs of modern large-scale farming, which pushes the whole industry to increase investment in research and development.   In terms of veterinary vaccines, multivalent combined vaccines that can prevent multiple animal diseases at the same time have become a popular research direction. Such products can effectively reduce the number of vaccinations, save labor costs for farms and improve immunization efficiency, so they are widely favored by overseas buyers. In the field of chemical veterinary medicines, new formulations with better absorption effect and lower drug residue are continuously launched, complying with the global trend of green and healthy breeding. In addition, traditional Chinese veterinary preparations, featured by natural ingredients and mild efficacy, have gradually gained recognition in many overseas markets and become a new highlight in export business.   The integration of technology and products also brings new opportunities for trade development. R&D institutions and production enterprises keep strengthening technical research to improve product performance and expand application scenarios. As innovative products continue to enter the global market, they not only enrich the product line of overseas suppliers, but also help exporters form differentiated competitive advantages. Looking ahead, the combination of technological innovation, quality upgrade and market exploration will continue to lead the development of veterinary foreign trade, and create more possibilities for cross-border cooperation in the animal health industry.

 0 I. Poultry Meat 1. The Proportion of Poultry Meat Continues to Rise In recent years, the proportion of poultry meat production in total meat output has shown a year-on-year upward trend, rising from 22.11% in 2016 to 30.91% in 2020. With the continuous maturity of white-feather broiler breeding technology and the popularization of frozen food, the China Merchants Industry Research Institute predicts that the proportion of China's poultry meat production in meat will rise to 35.39% in 2022.   Data source: National Bureau of Statistics, compiled by China Merchants Industry Research Institute 2. Poultry Meat Production Grows Steadily China's poultry meat production continued to grow from 2017 to 2019. In 2018, China's poultry meat output was 19.94 million tons, a year-on-year increase of 5.1%; in 2019, China's poultry meat output was 22.39 million tons, a year-on-year increase of 12.3%. The China Merchants Industry Research Institute predicts that China's poultry meat output will reach 24.624 million tons in 2022.   Data source: National Bureau of Statistics, compiled by China Merchants Industry Research Institute 3. Brazil Is China's Major Poultry Meat Importer From January to October 2021, China imported 1.2054 million tons of poultry meat, a year-on-year decrease of 3.8%, with an import value of 2.785 billion US dollars, a year-on-year decrease of 3.4%; exported 185,500 tons, a year-on-year increase of 15.5%, with an export value of 531 million US dollars, a year-on-year increase of 21.0%. Imports mainly come from Brazil (48.3% of total imports), the United States (24.5%), Russia (8.4%), Thailand (5.9%), Argentina (5.2%). Imports from the US decreased by 11.4% month-on-month, and the import proportion decreased by 4.7 percentage points month-on-month. By product category, chicken feet, frozen boneless chicken and frozen whole chicken account for 45.0%, 22.8% and 22.6% of imports respectively. Main exports go to China's Hong Kong, Macao regions, Bahrain, Cambodia, Mongolia, etc.   Data source: General Administration of Customs, compiled by China Merchants Industry Research Institute 4. Per Capita Consumption Increases Accordingly According to statistics from the National Bureau of Statistics, in recent years, China's per capita consumption of poultry meat has shown a steady growth trend. China's per capita demand for poultry meat increased year by year from 2017 to 2019. In 2018, China's per capita demand for poultry meat was 14.3 kg, a year-on-year increase of 4.95%; in 2019, China's per capita demand for poultry meat was 16.2 kg, a year-on-year increase of 13.41%. The China Merchants Industry Research Institute predicts that China's per capita consumption of poultry meat will reach 18.14 kg in 2022.   Data source: National Bureau of Statistics, compiled by China Merchants Industry Research Institute II. Chicken Meat 1. Chicken Meat Is an Important Part of Poultry Meat Chicken meat is the main component of poultry meat, accounting for 63% of poultry meat output in 2020. China's chicken meat processing is mainly concentrated in whole chicken processing and sales, with few deep-processed products, leading to reduced product quality, increased costs and weak market competitiveness. In 2020, China's chicken meat output reached 14.85 million tons, second only to pork in domestic consumption. It is expected that China's chicken meat output will reach 15.68 million tons in 2022.   Data source: USDA, compiled by China Merchants Industry Research Institute 2. Poultry Meat Prices Rise Breeding capacity reduction and increased consumption drive up poultry meat prices. In November 2021, the average market price of live chickens was 19.60 yuan per kilogram, up 2.3% month-on-month and 1.0% year-on-year; the average market price of white strip chickens was 21.82 yuan per kilogram, up 2.1% month-on-month and 2.1% year-on-year. From the perspective of breeding efficiency, the price of white-feather broilers continued to rise in November, reaching 7.75 yuan per kilogram in the 4th week, up 8.8% compared with the 4th week of October, with a profit of 0.56 yuan per kilogram, turning a profit for the first time since the 1st week of September 2021; the breeding profit of yellow-feather broilers continued to increase, rising from 0.3 yuan per kilogram last month to 1.2 yuan.   Data source: Ministry of Agriculture and Rural Affairs, compiled by China Merchants Industry Research Institute III. Future Outlook for Poultry Meat Production: It is expected that the slaughter volume of commercial poultry will increase slightly in the later period, ensuring sufficient market supply. Consumption: With the arrival of the Spring Festival holiday, the holiday effect will boost poultry meat consumption. In addition, the recent rise in pork prices will also drive poultry meat consumption. Comprehensive judgment: As the traditional consumption peak season approaches, poultry meat prices are expected to rise slightly with limited growth. With little change in breeding costs, breeding efficiency will continue to improve.

To further deepen agricultural cooperation between China and Iraq and advance the exchange and development of veterinary vaccines, an expert group from the Iraqi Ministry of Agriculture and officials of renowned enterprises paid an on-site inspection and exchange visit to Shandong Huahong Bioengineering Co., Ltd. from September 6 to 7, 2025. The visit aimed to explore trade cooperation opportunities in the field of veterinary vaccines and jointly boost the healthy and sustainable development of animal husbandry in both countries.   Warmly received by the senior management of Huahong Bio, the Iraqi delegation paid an in-depth visit to the company's production workshops, quality inspection center and laboratory animal houses. They gained a comprehensive understanding of the enterprise's advanced experience in veterinary vaccine research and development, production processes, quality control and technological innovation. The delegation spoke highly of Huahong Bio's sophisticated production equipment, rigorous quality management system and professional R&D capabilities.   Subsequently, the two sides held a cooperation negotiation meeting. Wang Yongming, General Manager of Huahong Bio, gave a detailed introduction to the company's product portfolio and highlighted the competitive edges of its products in the international market. The Iraqi delegation presented the domestic vaccine market demand and import policies, and expressed a strong desire to strengthen the national animal disease prevention and control system by introducing advanced Chinese veterinary vaccines. Targeting the local breeding characteristics in Iraq, both parties focused on discussing the application schemes of combined vaccines for poultry and sheep. To better meet the development demands of Iraq's animal husbandry industry, Huahong Bio put forward an advanced immunization optimization solution. This solution can cut immunization frequency by 40% while keeping the antibody qualification rate above 90%, effectively addressing various disease prevention and control challenges currently faced by Iraq.   Li Shicheng, Chairman of Huahong Biology, stated that this exchange marks a favorable start for bilateral cooperation. Going forward, the company will adhere to the principle of mutual benefit and win-win results, earnestly implement reached cooperation consensus, promote high-quality veterinary vaccine products to enter the Iraqi market, and contribute to boosting agricultural cooperation and livestock industry prosperity between China and Iraq. The in-depth communication between Huahong Biology and Iraqi counterparts will further strengthen China-Iraq cooperation in the field of veterinary vaccines. Both sides will jointly tackle global animal disease challenges and advance high-quality development of the livestock industry.  

Dynamic vitality fills the land of Tianfu. On May 18, 2026, the 23rd China Animal Husbandry Expo & 2026 China International Animal Husbandry Expo grandly opened at Western China International Expo City in Chengdu.     Ranking first in Asia and second worldwide among professional animal husbandry exhibitions, the event themed "Show New Forms, Share New Achievements, Boost New Momentum, Lead New Development". Covering an exhibition area of over 180,000 square meters, it boasts more than 8,300 booths, hitting a record high. Over 1,500 enterprises from 41 countries and regions worldwide participated.     A total of 123,000 visitors entered the venue on the opening day. The exhibition hall was crowded with brisk business negotiations. Industry practitioners gathered in Chengdu to seek technologies, discuss cooperation and seal orders, fully demonstrating the strong appeal of the expo.     Leading enterprises gather strength, whole industry chain achieves coordinated development   Well-known enterprises made a strong appearance, including Muyuan Group, Wens Foodstuff Group, Capital Agribusiness Group, CP Group, New Hope Liuhe, Tongwei Agriculture & Aquaculture, Twins Group, China Animal Husbandry Group, China Animal Husbandry Industry, Haid Group, Dekang Group, Shennong Group, Boen Group, Tielishi Group, Yangxiang Group, Dexing Group, Shanghai Xiangxin, Yisheng Livestock & Poultry Breeding, Anyo Group, World Stock Group, Huayu Agriculture, Xiaoming Agriculture & Animal Husbandry, Shunxin Agriculture, Shiji Biotechnology, Shendan Group, Huamei Livestock and Poultry, Fujian Yongcheng, China National Breeding Swine, Juxing Agriculture & Animal Husbandry, Huatian Seed Industry, Sichuan Hengtong, Tiaozhan Group, Guangzhou Guangxing, Henan Wanhua, Shengxing Technology, Little Giant Group, Huali Stock and Agri-credit Internet.     Many large-scale enterprises showcased their complete industrial chains, covering breeding, feed production, livestock raising, slaughtering and processing as well as food sales. It fully demonstrates the industry's determination to shift from scale expansion to quality and efficiency improvement.         Well-divided exhibition areas, one-stop docking   Centered on breeding enterprises, this Livestock Expo has scientifically arranged 11 major professional exhibition areas, including group exhibition zone, large enterprise exhibition zone, pig breeding zone, poultry breeding zone, pig farming equipment zone, poultry farming equipment zone, international exhibition zone, animal health and feed zone, specialty livestock product food zone, environmental protection zone and outdoor equipment zone. It builds a panoramic and one-stop platform for industrial exhibition and communication, enabling efficient integration and precise docking of resources across the entire industrial chain.     International exchanges bring prosperity across the globe   Exhibition groups from the United States, France, the Netherlands and Northern Europe have gathered again in the international exhibition area, bringing world-leading technologies including intelligent breeding equipment, precision feeding systems, digital pasture management solutions and animal welfare standard systems.   From international exhibition delegations and matchmaking meetings to technology demonstrations and practical cooperation, the Animal Husbandry Expo serves not only as a showcase for global animal husbandry products, but also a hub for in-depth integration of international industrial, supply and value chains.   Rural Revitalization, Joint Progress Towards Common Prosperity   This Livestock Expo specially sets up an exhibition area for consolidating poverty alleviation achievements and advancing rural revitalization. It showcases local distinctive livestock and poultry breeding achievements and typical rural revitalization cases, contributing the strength of animal husbandry to consolidating and expanding poverty alleviation gains and comprehensively promoting rural revitalization.     The 2nd (2026) Apiculture Development Conference held concurrently alongside the "520 World Bee Day" event serves as a vivid epitome of boosting comprehensive revitalization by nurturing niche industries. Though the apiculture sector is small in scale, it integrates multiple values including ecological conservation, increased farmers' income and honey-related economy. Centering on the industrial upgrading and brand building of apiculture, the conference strives to help this distinctive industry play a greater role in rural revitalization via technical exchanges, production-marketing docking and popular science promotion.     Scientific and Technological Innovation, Achievement Exhibition   During this Livestock Expo, the China Animal Agriculture Association, together with ten national industrial technology systems covering live pigs, laying hens, broilers, waterfowl and other fields, jointly held the event themed Exhibition and Promotion of Scientific and Technological Innovation Achievements in Animal Husbandry since the 18th National Congress of the Communist Party of China. It showcases landmark and pioneering scientific and technological innovations spanning key links of the entire industrial chain, including germplasm innovation, epidemic prevention and control, smart breeding, green low-carbon development, feed nutrition, processing and quality safety, fully demonstrating the robust strength of China's animal husbandry technological innovation over the period.   This promotion event serves as a comprehensive review of the industry's innovative endeavors in the past years and a powerful mobilization for future development. It aims to accelerate the transformation of advanced and applicable scientific and technological achievements from laboratories to industrial sites, and continuously fuel the high-quality development of the animal husbandry sector.     High-quality development, integration of industry and finance   The 3rd High-quality Animal Husbandry Development Conference will be held concurrently. In-depth discussions will be conducted on topics including the 15th Five-Year industrial policies, economic situation, corporate overseas expansion and synthetic biotechnology. The conference will also set up a special session on corporate merger, acquisition, docking and integration as well as strategic investment management consulting, building a high-end platform for capital connection and strategic consultation in the industry.   Consumption Engine, Brand Empowerment     To thoroughly implement the requirements of the 2026 Central Government No.1 Document on promoting the quality and efficiency of the "vegetable basket" industry and taking multiple measures to boost the consumption of livestock products, a premium livestock products exhibition area has been set up in a prominent location within the exhibition hall. Featured products such as Xinjiang Wangyuan camel milk ice cream, Dong'e donkey meat products, Chongqing Hengdu beef products, rabbit meat products, pigeon meat products, and honey are showcased at the event, presenting a collection of specialty and high-quality livestock products from across the country.     Additionally, a large-scale public welfare tasting and promotion event titled "Savor Livestock Delicacies, Taste Tianfu Flavors" will be held. It brings together specialty foods from numerous enterprises and invites over a thousand attendees for on-site tasting, driving industrial upgrading through consumption upgrading.     All-media Matrix, Expanding Influence Beyond Boundaries   This Animal Husbandry Expo has attracted extensive attention from over a hundred mainstream and new media platforms, including CCTV.com, Farmers' Daily, the official website of China Animal Agriculture Association, China Animal Husbandry Media, China Animal Husbandry & Veterinary News and overseas media. Adopting full-cycle publicity covering pre-event promotion, on-site coverage and post-event summary, it builds an integrated online-offline media matrix to fully showcase the grand occasion of the expo.   Twenty-three years of dedication with an unwavering original aspiration. The booming opening day scene bears witness to the resilience, vitality and innovation potential of China's animal husbandry industry. Covering high-quality livestock products, intelligent equipment, industrial chain clusters and cross-border cooperation, the Animal Husbandry Expo gathers global innovation momentum as a vital convergence platform.   Exchanges of ideas, business transactions and in-depth cooperation will keep unfolding here. Standing at the starting year of the 15th Five-Year Plan, let us target high-quality development and embrace this grand gathering of animal husbandry practitioners in Chengdu.   Disclaimer: Part of the materials are sourced from the Internet with specified origins. All copyrights belong to the original authors. The content is for reference only. Please contact us promptly for removal if any copyright infringement occurs.

(Source: China Swine Industry) On May 15, Jinyu Bio-technology Co., Ltd. (hereinafter referred to as Jinyu Bio), a leading listed enterprise in China's veterinary biopharmaceutical sector, unveiled the latest progress in its research and development of African Swine Fever (ASF) vaccines. The jointly developed ASF subunit vaccine is advancing steadily in clinical trials. The second virus challenge test has verified its excellent protective efficacy, marking a major breakthrough in phased research achievements.   Recently, Jinyu Bio (600201) responded to inquiries regarding the results of the second-round virus challenge test of the ASF vaccine on an interactive platform, stating: "The second round of virus challenge test for the ASF subunit vaccine has been completed as scheduled. Unblinded data indicates the test results fully meet the evaluation criteria of this clinical trial, and the vaccine efficacy is in line with expectations. The company will subsequently finish the statistical analysis of all clinical trial data and submit an official registration application."   Protective Effect Validated from Large-scale Vaccination to Two Rounds of Virus Challenge Highly contagious and lethal, African Swine Fever virus has long hindered the stable development of China's pig breeding industry. Safe and effective preventive vaccines represent a crucial area urgently needing breakthroughs for the sector. Since 2019, aligning with the national animal biosafety strategy, Jinyu Bio has launched a special R&D program for ASF vaccines. After seven years of continuous technological research, the company has invested nearly 600 million yuan in relevant development.   To diversify research approaches and mitigate technical risks, the enterprise has proactively established a multi-dimensional R&D system, simultaneously developing four technical routes: gene-deleted live vaccine, vector vaccine, subunit vaccine and mRNA vaccine. The subunit vaccine that achieved the phased clinical trial breakthrough is a vital outcome of the company's parallel multi-technology development strategy.   Reviewing the research and testing process, Jinyu Bio (600201) completed large-scale immunization vaccination at its first clinical trial site in October 2025, officially entering the in-vivo observation phase. In January 2026, the firm finished the first high-dose virus challenge test. The test adopted oral spraying to simulate natural infection, with an ultra-high challenge dose of 8000 HAD50, rigorously examining the vaccine's protective performance under extreme experimental conditions.   Test data showed that within the 28-day observation period, pigs in the immunized group reached qualified protection indicators. In contrast, all pigs in the non-immunized control group contracted the disease and died, registering a 100% mortality rate, which strongly confirmed the vaccine's protective effect.   The phased clinical trials of the vaccine have been successfully completed. The company will conduct systematic statistics and in-depth analysis on trial data, compile clinical trial summary reports, and submit new veterinary drug registration applications with complete documents in accordance with regulations. Pursuant to relevant veterinary drug approval rules, the vaccine has to go through statutory procedures including technical review, on-site verification of clinical trial data and production site inspection. Only after passing all reviews can it obtain the veterinary drug registration approval and be put into production and market launch.   Relevant officials of Jinyu Bio told journalists, "The entire clinical trial was carried out in strict compliance with Good Clinical Practice guidelines for veterinary drugs. We have built a sound data recording and traceability system. The clinical manifestations, physiological indicators and viral load changes of experimental pigs were monitored at multiple time points over a long period, fully ensuring the authenticity, rigor and traceability of trial data."    ASF Subunit Vaccine Suits Regular Epidemic Prevention Needs of Large-scale Pig Farms Industry insiders stated that technically different from traditional inactivated vaccines and gene-deleted vaccines, the ASF subunit vaccine developed by Jinyu Bio contains no live virus components. It poses no biosafety risks such as virus virulence reversion and virus shedding and spread in breeding environments. The vaccine fits China's large-scale and intensive pig breeding model, striking a balance between safety and protective effectiveness fundamentally.   Furthermore, the successful 120-day immune duration test proves the vaccine's long-term protective capacity. Matching the growth cycle of pigs, it can effectively satisfy regular epidemic prevention demands of large-scale pig farms.   From the industrial perspective, China boasts a huge pig breeding market with strong rigid demand for ASF prevention, leaving a long-term supply gap for high-quality vaccines. Once approved, the vaccine will further improve domestic pig disease prevention and control systems, cut down infection risks in the breeding industry and reduce economic losses of the sector.   For the enterprise itself, this research achievement will enrich its product portfolio, strengthen core industrial competitiveness and drive medium and long-term business growth, presenting promising commercial prospects.   (Source: Cls.cn, Securities Daily, Sina Finance)

On December 24, 2025, Mr. Jawid Tasal, a distributor from Afghanistan, visited Huahong Biotechnology for inspection and exchange. Li Shicheng, Chairman of Huahong Company, and his team gave him a warm reception. The two sides conducted in-depth discussions on issues including international market cooperation.     At the forum, Deputy General Manager Li Xiaoxia elaborated on Huahong Company's vision for international cooperation. She stressed that the visit of dealer representatives serves as a vital opportunity for both sides to deepen mutual understanding and expand cooperation. The company will promote bilateral cooperation with utmost sincerity to achieve mutual benefit and win-win results. Wu Haizhen, Director of the Technical Inspection Center, delivered a comprehensive report covering the company's development history, research and development achievements and product portfolio, enabling foreign representatives to gain an in-depth insight into Huahong's strength.   After the meeting, Deputy General Manager Li Xiaoxia accompanied Mr. Javed Tassar on an on-site inspection of the factory area, and held discussions with staff from the Technology Department, Marketing Department, Quality Management Department, Production Department and other relevant departments.   This foreign inspection activity not only helps foreign partners fully recognize Huahong's comprehensive strength, but also builds a solid bridge for Huahong's products to enter the global market. Going forward, Huahong Company will consistently uphold an open and cooperative attitude, actively explore international markets, forge ahead hand in hand with global partners, and pursue common development based on mutual benefit.    

On October 30, a delegation from the S.N. Vyshelessky Institute of Experimental Veterinary Medicine of the National Academy of Sciences of Belarus and researchers from the Poultry Research Institute of Shandong Academy of Agricultural Sciences visited Shandong Huahong Bioengineering Co., Ltd., launching an in-depth exchange focusing on poultry disease prevention and control, healthy breeding and the research and development of biological product technologies.     During the communication, leaders from the National Academy of Sciences of Belarus and the Poultry Institute of the Provincial Academy of Agricultural Sciences gained a comprehensive understanding of the company's product lineup and its competitive edges in the international market. Warmly received by senior management of Huahong Bio, the delegation paid an in-depth visit to the company's vaccine production workshops and learned about its advanced experience in the production process of veterinary vaccines. They spoke highly of the sophisticated production equipment, stringent quality management system and professional research and development capabilities of Huahong Bio, laying a solid industrial foundation for future cooperation between the two sides in the field of biological products.   At the corporate cooperation level, Shandong Huahong Bioengineering Co., Ltd., as the enterprise representative in this exchange, focused on discussing ways to enhance external publicity, expand international markets and boost the export of biological products through international cooperation. The three parties reached a consensus that enterprises, as vital carriers for the commercialization of scientific research achievements, should give full play to market advantages, deepen cooperation with research institutions in China and Belarus, and jointly build internationally competitive brands of biological products. Meanwhile, leveraging international cooperation platforms under the Belt and Road Initiative, enterprises shall actively take part in international agricultural exhibitions and technical exchanges to raise their global popularity and influence. This will facilitate trade of biological products between China and Belarus and drive high-quality development of the agricultural industries of both countries.   The exchange between the delegation from the S.N. Vyshelessky Experimental Veterinary Institute of the National Academy of Sciences of Belarus, the Poultry Research Institute of Shandong Academy of Agricultural Sciences and Shandong Huahong Bioengineering Co., Ltd. has not only deepened mutual understanding between China and Belarus in the poultry industry, but also established a new mechanism for coordinated cooperation between scientific research institutions and enterprises. Going forward, the three parties will take this exchange as an opportunity to further deepen cooperation in reserve project application, joint research and enterprise collaboration. They will advance the transformation and application of agricultural scientific and technological achievements between the two countries, contribute more to international agricultural cooperation under the Belt and Road Initiative, and jointly create a new chapter in agricultural exchanges and cooperation between China and Belarus.  

To deepen technological exchanges and trade cooperation between China and Pakistan in agriculture and animal husbandry, and boost the coordinated development of the veterinary vaccine industry, Dr. Sami, a core researcher from Pakistan's U.M. Enterprises, recently paid an on-site visit and held cooperation negotiations with Shandong Huahong Bioengineering Co., Ltd. The two sides conducted in-depth discussions on veterinary vaccine technological innovation, product adaptation and market collaboration, injecting new momentum into the sound and sustainable development of animal husbandry in both countries.   Senior management of Huahong Biotechnology extended a warm welcome to Dr. Sammy and accompanied him on a comprehensive tour of the production workshops, warehouses, quality inspection rooms and laboratory animal houses. During the visit, Dr. Sammy gained in-depth insights into the practical experience of Huahong Biotechnology in veterinary vaccine research and development, production process control and quality standard system construction. He paid close attention to the production technologies and technical parameters of vaccines for poultry and sheep. Dr. Sammy spoke highly of the advanced production equipment introduced by the company, the strict raw material traceability system, as well as the laboratory's precise detection capability for vaccine potency and safety. The visit fully demonstrated the professionalism and innovative strength of Chinese veterinary vaccine enterprises, laying a solid foundation for future cooperation between the two sides.     At the subsequent cooperation negotiation meeting, Wang Yongming, General Manager of Huahong Biotechnology, systematically introduced the company's core product portfolio, including flagship products such as avian salmonella vaccines and peste des petits ruminants vaccines. Combined with international market feedback, he highlighted the competitive edges of the products in immune efficacy, cost performance and adaptability. On behalf of Pakistan's U.M. Company, Dr. Sami shared the current development status of Pakistan's animal husbandry, bottlenecks in animal disease prevention and control, and market demand for vaccines.   Li Shicheng, Chairman of Huahong Biotechnology, stated during the negotiation that China and Pakistan boast a solid foundation in agricultural cooperation. As a key enterprise in Pakistan's animal health and feed industry, U.M. Company shares highly consistent technological concepts and market resources with Huahong Biotechnology. Dr. Sami's visit marks an important starting point for the two sides to establish long-term cooperative ties. Going forward, adhering to the principle of mutual benefit and win-win results, Huahong Biotechnology will leverage its strengths in research, development and production to jointly explore cooperation models including technology sharing, customized product development and joint market development with U.M. Company. It will help Pakistan improve its animal disease prevention and control system and advance the coordinated development of animal husbandry in both countries.     Dr. Sami also stated that through this field inspection, he deeply recognized Huahong Bio's technical strength and sense of responsibility in the field of veterinary vaccines. He looks forward to carrying out in-depth cooperation with Huahong Bio, introducing China's advanced vaccine technologies and optimized solutions to Pakistan, supporting the high-quality development of local animal husbandry, and further deepening the friendly cooperation between China and Pakistan in the agricultural sector.   The exchange and negotiation between Dr. Sami from Pakistan's U.M. Company and Huahong Biotechnology has not only built a targeted cooperation platform for both sides, but also blazed a new trail for collaborative innovation in the veterinary vaccine industry of China and Pakistan and joint efforts to tackle global animal disease challenges. The two parties will take practical actions to advance cooperation implementation and write a new chapter in agricultural trade cooperation between China and Pakistan.

一、百亿宠物疫苗逆势上扬，市场规模突破百亿     进口疫苗的市场份额正进一步萎缩。国产替代将如何重塑百亿宠物疫苗市场版图？   2024 年，我国人均 GDP 已高达 9.57 万元，约合 1.4 万美元。与此同时，宠物经济规模也水涨船高，据艾瑞咨询数据预测，2024 年市场规模将突破 3453 亿元。早在 2010 年前后，我国人均 GDP 跨越 4000 美元大关时，一批敏锐的国内企业便捕捉到了宠物经济市场的巨大潜力，布局宠物医药领域。然而，在宠物医药产品中，宠物疫苗是技术壁垒很高的 “硬骨头”。毒株筛选、佐剂研发、工艺落地等核心环节突破任何一个都极具难度。长期以来，国内宠物疫苗市场一直被硕腾、默沙东等国际巨头主导，占据了 90% 的市场份额。但近年来，形势开始变化。2023 年，我国首批国产猫三联疫苗成功通过农业农村部应急评价，正式上市，标志着宠物疫苗国产替代大幕拉开。国产宠物疫苗一经上市，便展现出了强劲的市场竞争力。海关总署数据显示，进口宠物疫苗的数量和金额已连续六个季度呈现 “双降” 态势。《2025 中国宠物医疗行业白皮书》更是指出，自 2024 年 4 月起，国产疫苗市场份额稳步攀升，外资疫苗的 “霸权” 地位正逐渐被动摇。如今，国产宠物疫苗正以破竹之势，打破外资巨头的长期垄断格局，进口疫苗的市场份额正一步步萎缩。     宠物疫苗市场具有显著的逆周期属性。在当前消费需求不足大环境下，宠物疫苗市场仍然保持着高增长。有调研结果显示，无论是在中国还是全球其他地区，当收入降低 20% 时，大部分人最不愿减少的是宠物消费开支。爱宠生物副总裁刘洋告诉动脉网：“保守估计来看，目前宠物疫苗市场规模已突破百亿元，其中强制免疫的狂犬疫苗贡献 30-40 亿元基本盘，猫三联与犬联苗分别形成 20-30 亿元、20 亿元量级细分市场，并且保持每年的快速增长，参考海外宠物市场的发展，未来 5 年都是宠物疫苗发展的黄金期。”   国内宠物疫苗市场有两大核心引擎驱动增长：   宠物数量持续增长：《2023-2024 年中国宠物行业白皮书》数据显示，我国城镇猫犬数量已经超 1 亿只，这一数量已经超过 2024 年新增新生儿数量。 宠物主防疫意识提升：相比欧美发达国家宠物就诊率，国内宠物的就诊率较低，宠物疫苗的渗透率也处于较低水平。以猫三联为例，国内接种渗透率不足 10%，市场还有很大的提升空间。近年来，国内宠物主防疫意识提升，更多宠物主人愿意通过疫苗降低宠物生病风险。     在百亿宠物疫苗市场，“妙三多” 曾是一个难以撼动的符号。作为硕腾旗下独家猫三联疫苗品牌，该产品自 2011 年获得正式批文进入中国市场以来，是长期唯一正式获批的猫三联疫苗产品。2023 年前，国内猫三联疫苗就等同于 “妙三多”。这个现象折射出更深的行业图景：不止猫三联疫苗，兽用狂犬苗、犬联苗等宠物疫苗核心品类同样由硕腾、英特威、勃林格等外资巨头主导，市场份额超过 90%。   近年来，国产企业逐渐在核心宠物疫苗品类取得突破，多款国产猫三联疫苗获批上市，国产疫苗开始撕开外资构筑的防线。 二、国产疫苗的三大突围路径：毒株适配、工艺升级、产品创新     随着国产企业研发管线突破，这个外资主导的市场正迎来价值重估。目前，国产宠物疫苗企业数量超过十家。国产入局者可以分为两大类：一是以瑞普生物、普莱柯为代表的传统兽药背景派，二是以爱宠生物、海正动保为代表的从人用药领域跨界的技术降维派。这两大阵营正从毒株适配、工艺升级、产品创新三个维度构筑竞争壁垒。   1. 毒株适配：国产疫苗的天然优势     全球各地流行毒株的基因群不同，疫苗的毒株与流行毒株不匹配，疫苗的保护力会大打折扣。国内宠物疫苗基于本土流行毒株进行分离，毒株适配度更高。以猫三联为例，对于猫三联中的三个毒株，疱疹病毒和细小病毒为 DNA 病毒，很少出现变异。而杯状病毒则为单链 RNA 病毒，RNA 病毒在复制过程中，其 RNA 聚合酶缺乏校对功能，导致复制过程中错误率增加，从而产生变异的概率大大增加。根据中金报告，硕腾 “妙三多” 猫三联疫苗采用美国分离毒株 FCV255 株，且自 2011 年进入中国市场后近 10 年未曾更新。   2. 工艺升级：跨界企业的降维打击     疫苗生产涉及几十道工艺，生产工艺会影响疫苗的纯度和抗原含量。刘洋表示：“在宠物疫苗生产领域，海外多家企业通常采用兽用生物制品的工艺路线进行设计，兽用疫苗为养殖大动物设计。而宠物通常体型更小，对生物制品的反应更敏感，更容易产生副反应，因此对于产品质量细节要求更高。在生产工艺上，从人用医药跨界到宠物疫苗的企业更具优势，其生产工艺会参考严苛的人用疫苗标准，使得产品更加稳定和有效，发生副作用情况更少。”   3. 产品创新：开辟全新赛道     创新突围也是国产宠物疫苗锻造竞争力的方向，通过开创新赛道的方式，找到新市场。宠物疫苗创新的路径包括研发覆盖新病种的全新疫苗、疫苗覆盖更多亚型、减少接种次数。绝育疫苗就是一个国产全球创新的重磅产品。现有的宠物绝育方式是手术绝育，手术绝育需要麻醉，也带来潜在的并发症风险，也有悖于动物福利。而绝育疫苗是通过生物工程方法使其短期失去生育能力，只需要一年注射一针，大大提高便捷性和降低宠物主人的绝育成本。这一产品全球尚未有同类产品上市，而中国企业已经抢先布局研发。据悉，艾益动物药品节育疫苗已进入临床阶段，爱宠生物绝育疫苗预计今年将进入临床试验阶段。在前沿的 mRNA 疫苗领域，也有多家国产宠物疫苗企业布局。2025 年，瑞普生物 mRNA 疫苗生产线已通过兽药 GMP 现场检查静态验收，计划研发猫四联 mRNA 疫苗。   宠物疫苗研发流程如下：   POC（概念验证）：先在中国本地找到一些发病动物，然后从它们的血液、体液等组织中，找到相应的病原体，再分离出来，针对这些毒株开展病毒学或细菌学的操作，将其减毒、驯化到所需要的方向上，获得疫苗株，开展样品生产与基本的测试。 Lab Study（实验室研究）：也可称为临床前研究阶段，主要目标就是根据监管法规的要求，把动物的安全性、有效性实验都做完全，利用 SPF 级别的实验动物完成疫苗的测试，并生产中试样品，制定质量标准。这些环节整体相当于人用药物开发中，从临床前一直到 Ⅲa 期的实验。 Field Study（田间研究）：或者称临床研究阶段，就是要在更大规模下，GCP 的管理规范下，至少入组几百只动物去验证之前在实验室阶段得到的结果，相当于人用药开发中的 Ⅲb 期实验。或者称为 Pivotal Study 关键性临床，所有前期关键数据都将在更大的样本量上做验证。 兽药注册：注册过程中会有一些评审流程，以及监管机构开展复核检验的过程。     三、国产疫苗的短板与破局：渠道与出海     在产品竞争上，国产宠物疫苗企业可以交出漂亮的答卷。以爱宠生物为例，其狂犬灭活疫苗在农业部中检所报告中，疫苗效价达到 8.3 iu，而国家标准是疫苗效价不低于 2iu。这个水平也超过了外资产品表现。瑞普生物旗下国产猫三联产品 “喵瑞舒” 上市半年发货 100 万头份，首月销售额破千万。但在渠道上，国产企业还需要打破铁幕。   1. 渠道短板：外资的专业壁垒     外资企业仍然牢牢把控专业渠道。国产替代的深层挑战在于能否拿下专业渠道，目前，国内企业相比于外资企业在渠道能力上还存在短板。宠物疫苗市场以宠物医院为主，而高端连锁宠物医院正是外资品牌大本营。以硕腾为例，硕腾与新瑞鹏、瑞派等国内主要连锁宠物医院达成深度合作。外资品牌依靠全球影响力和口碑，在宠物医疗专业渠道议价能力很强。而新生的国产品牌还需要时间积累影响力。业内人士表示：“外资企业如硕腾长期深耕专业宠物医院、连锁医院这一类专业渠道，和医院形成了强绑定的关系。而国内企业更多依赖经销商渠道，和国内专业医疗机构关联较少。国内外企业在经销商网络成熟度上也有差距。跨国企业积累了丰富的渠道管理经验。外资企业经销商网络层级清晰、管理规范，经销商网络具备专业的服务能力。而国内企业近年来才开始进行渠道建设，经销商体系相对分散，经销商服务能力相比于外资企业较弱。”     国内外企业在服务和技术支持方面也存在差距。外资企业可以提供疫苗配套的检测服务、免疫方案设计，以及和宠物医生的培训互动，通过这些教育性和培训性的项目把产品理念植入到医生群体中，促使宠物用药的不断增长，以及以此来增加和宠物医生粘性。而国产宠物疫苗企业和宠物医生的互动往往停留在产品销售层面。对于服务能力提升，国产企业也在努力补齐能力。通过定期举办兽医培训，举办临床案例分享会以及学术会议拉近与兽医之间的关系，提升医生对于国产宠物疫苗的信任。   2. 破局之道：出海开辟新战场     当国产宠物疫苗参与者增多，难以避免价格战。有投资人曾对动脉网表示，认为国内宠物疫苗企业进入者增多，市场已经趋于白热化。价格战不利于行业长期发展，宠物疫苗行业需要持续的研发投入，而低价导致利润减少会影响企业后续的技术创新和研发投入，影响行业的长期可持续发展。低价竞争带来的成本压力也会带来影响产品质量的风险，损害消费者对于国产疫苗的信任度。价格战从短期来看可以扩大市场份额，但从长期来看是一种短视的行为。国产疫苗发力更应该从研发端、产品端、供应端发力，而非通过价格战方式进行恶性竞争。   告别内卷并非放弃竞争，出海也是国产宠物疫苗方向。艾益动物药品团队熟悉全球 60 多个国家的动物疫苗的外资注册法规，艾益动物药品创始人朱贤主曾在采访中表示：从国际范围来看，中国目前在动物疫苗领域已经有了很高标准的法规体系，许多国家认可中国监管机构颁发的兽药 GMP 证书等资质，中国开发和生产的高品质宠物疫苗，未来有很好的出海机会。从区位来看，中国可以辐射亚洲多个国家，亚洲国家之间的区域流行毒株情况相似，疫苗匹配性更好。东南亚市场是国内宠物疫苗企业出海的第一站。从人均 GDP 上看，东南亚多个国家人均 GDP 超过 4000 美元，东南亚市场正处于高速增长阶段，但是当地缺乏生产宠物疫苗的能力，在宠物疫苗供应上同样依赖外资，国内企业切入东南亚市场有利于抢占先机。     宠物疫苗是一个消费属性和医疗属性叠加的市场。国内新增宠物增速放缓，站在宠物医疗产业升级的转折点上，国产疫苗企业正面临历史性的选择：是困在低价竞争的泥潭中消耗创新元气，还是以技术突破为矛、以服务生态为盾，在全球市场开辟新战场？行业的破晓时刻，永远属于那些把实验室数据转化为临床信任、将渠道短板锻造成服务长板的企业。  

 Driven by the large-scale development of the global livestock and poultry breeding industry, the internationDrivenal market demand for high-quality veterinary drugs and vaccines continues to grow steadily, especially for antibiotics, antiparasitics, poultry vaccines and disinfectants.   At present, major markets including the EU, the Middle East, South Asia and Southeast Asia have raised stricter requirements for the production standards, registration procedures and dossier preparation of veterinary products. A GMP-based production system, complete quality traceability capabilities, and accurate grasp of the regulatory rules of target markets have become key competitiveness for animal health enterprises to expand into international markets. Looking ahead, the industry will continue to develop in a compliant and professional direction, and enterprises with international registration capabilities and stable supply capacity will usher in more market opportunities.